These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20595015)

  • 21. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
    Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
    Wallentin L; Varenhorst C; James S; Erlinge D; Braun OO; Jakubowski JA; Sugidachi A; Winters KJ; Siegbahn A
    Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of ADP-induced intracellular Ca2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1.
    Fox SC; Behan MW; Heptinstall S
    Cell Calcium; 2004 Jan; 35(1):39-46. PubMed ID: 14670370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
    Bierend A; Rau T; Maas R; Schwedhelm E; Böger RH
    Br J Clin Pharmacol; 2008 Apr; 65(4):540-7. PubMed ID: 17995973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study.
    Schuette C; Steffens D; Witkowski M; Stellbaum C; Bobbert P; Schultheiss HP; Rauch U
    Cardiovasc Diabetol; 2015 Feb; 14():15. PubMed ID: 25645908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
    Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A
    Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
    Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
    Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study.
    Furtado RHM; Giugliano RP; Strunz CMC; Filho CC; Ramires JAF; Filho RK; Neto PAL; Pereira AC; Rocha TR; Freire BT; D'Amico EA; Nicolau JC
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):275-284. PubMed ID: 27289472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
    Judge HM; Patil SB; Buckland RJ; Jakubowski JA; Storey RF
    J Thromb Haemost; 2010 Aug; 8(8):1820-7. PubMed ID: 20492465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes.
    Crimi G; Somaschini A; Cattaneo M; Angiolillo DJ; Piscione F; Palmerini T; De Servi S
    Platelets; 2018 May; 29(3):309-311. PubMed ID: 29206072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance.
    Dorsam RT; Murugappan S; Ding Z; Kunapuli SP
    Hematology; 2003 Dec; 8(6):359-65. PubMed ID: 14668029
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
    Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention.
    Ahn SG; Lee SH; Sung JK; Kim JY; Yoon J
    Platelets; 2011; 22(4):305-7. PubMed ID: 21480769
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
    Morel O; El Ghannudi S; Jesel L; Radulescu B; Meyer N; Wiesel ML; Caillard S; Campia U; Moulin B; Gachet C; Ohlmann P
    J Am Coll Cardiol; 2011 Jan; 57(4):399-408. PubMed ID: 21251579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals.
    McGlasson DL; Shah AD; Fritsma GA
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):583-7. PubMed ID: 21799401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction.
    Schäfer A; Flierl U; Kössler J; Seydelmann N; Kobsar A; Störk S; Bauersachs J
    Thromb Haemost; 2011 Jul; 106(1):141-8. PubMed ID: 21655677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.